HONG KONG – Chinese drug regulators have approved the first homegrown biosimilar, Shanghai Henlius Biotech Inc.'s HLX-01, a biosimilar referencing Roche Holding AG's Mabthera (rituximab), to treat non-Hodgkin lymphoma (NHL). It will be marketed as Hanlikang.